Navigation Links
Pharmos Announces Clinical Results from Phase 2a Trial of Topical Diclofenac NanoEmulsion Cream
Date:11/19/2008

(IBS) currently enrolling in a 480 patient Phase 2b trial.

About Pharmos Corporation

Pharmos discovers and develops novel therapeutics to treat a range of indications including specific diseases of the nervous system such as disorders of the brain-gut axis (IBS), pain/inflammation, and autoimmune disorders. The Company's lead product in development, dextofisopam, is undergoing Phase 2b testing in IBS patients. Dextofisopam has completed a Phase 2a IBS study in which it demonstrated a statistically significant effect compared to placebo on the primary efficacy endpoint of adequate relief (n=141, p=0.033). The Company also has a proprietary technology platform focusing on discovery and development of synthetic cannabinoid compounds with a focus on CB2 receptor selective agonists. Various CB2-selective compounds from Pharmos' pipeline have completed preclinical studies targeting pain, multiple sclerosis, rheumatoid arthritis, inflammatory bowel disease and other disorders. These are available for licensing / partnering.

SafeHarbor Statement

Statements made in this press release related to the business outlook and future financial performance of Pharmos, to the prospective market penetration of its drug products, to the development and commercialization of its pipeline products and to its expectations in connection with any future event, condition, performance or other matter, are forward-looking and are made pursuant to the safe harbor provisions of the Securities Litigation Reform Act of 1995. Such statements involve risks and uncertainties that may cause results to differ materially from those set forth in these statements. Additional economic, competitive, governmental, technological, marketing and other factors identified in Pharmos' filings with the Securities and Exchange Commission could affect such results.


'/>"/>
SOURCE Pharmos Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Celator(R) Pharmaceuticals Announces Enrollment of First Patient in Phase 2 Study with CPX-351
2. Portola Announces Data Showing Its Anti-Platelet Drug Inhibits Platelets in Clopidogrel (Plavix(R)) Non-Responders
3. ViroPharma Announces Presentation of Cinryze(TM) Data in Acute Treatment of Hereditary Angioedema
4. Alba Therapeutics Announces Enrollment of Its First European Patient in Global Phase IIb Study of Larazotide Acetate for Treatment of Active Celiac Disease
5. Raptor Pharmaceuticals Corp. Announces Positive Phase IIa Clinical Study Results for Convivia(TM) Program
6. Anesiva Announces Adlea ACTIVE-1 Phase 3 Clinical Results, Ceasing of Zingo Commercial Operations and Restructuring
7. Diagenic Announces Launch of First Breast Cancer Gene-Expression Blood Test
8. VIA Pharmaceuticals Announces Positive Results of Phase 2 Studies of VIA-2291 in Patients With Serious Cardiovascular Disease
9. Celladon Announces Presentation of Clinical Data From First-in-Human MYDICAR(R) Trial for Advanced Heart Failure at American Heart Association Scientific Sessions
10. Portola Announces Data Presentations Relevant to Its Lead Phase II Antithrombotic Compounds at American Heart Association Scientific Sessions 2008
11. Poniard Pharmaceuticals Announces Final Top-Line Results from Phase 1 Trial Demonstrating Positive Bioavailability with Oral Picoplatin
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/6/2015)... Inc. (Nasdaq: CRDC ) today announced financial results ... Cardica,s management will hold a conference call at 4:30 ... provide an update on the company,s business. ... 2015, we reintroduced a modified MicroCutter XCHANGE® 30 suitable ... commercial release is focusing primarily on customers in Europe ...
(Date:5/6/2015)... May 6, 2015 Vanda Pharmaceuticals Inc. (Vanda) ... results for the first quarter ended March 31, 2015. ... record quarter for product sales driven by HETLIOZ and ... accessing the 80,000 Non-24 patients in the U.S., the ... patent exclusivity for Fanapt underscores the growth potential of ...
(Date:5/6/2015)... Systems, Inc. (NASDAQ: DCTH ), a specialty pharmaceutical ... emphasis on the treatment of primary and metastatic liver ... March 31, 2015.  Highlights of the ... quarterly product revenue of $0.44 million, an increase of ... 2014; , Activated a prospective patient registry in ...
Breaking Medicine Technology:Cardica Announces Fiscal 2015 Third Quarter Financial Results 2Cardica Announces Fiscal 2015 Third Quarter Financial Results 3Cardica Announces Fiscal 2015 Third Quarter Financial Results 4Cardica Announces Fiscal 2015 Third Quarter Financial Results 5Cardica Announces Fiscal 2015 Third Quarter Financial Results 6Vanda Pharmaceuticals Reports First Quarter 2015 Financial Results 2Vanda Pharmaceuticals Reports First Quarter 2015 Financial Results 3Vanda Pharmaceuticals Reports First Quarter 2015 Financial Results 4Vanda Pharmaceuticals Reports First Quarter 2015 Financial Results 5Vanda Pharmaceuticals Reports First Quarter 2015 Financial Results 6Vanda Pharmaceuticals Reports First Quarter 2015 Financial Results 7Vanda Pharmaceuticals Reports First Quarter 2015 Financial Results 8Vanda Pharmaceuticals Reports First Quarter 2015 Financial Results 9Vanda Pharmaceuticals Reports First Quarter 2015 Financial Results 10Vanda Pharmaceuticals Reports First Quarter 2015 Financial Results 11Vanda Pharmaceuticals Reports First Quarter 2015 Financial Results 12Delcath Reports 2015 First Quarter Financial Results 2Delcath Reports 2015 First Quarter Financial Results 3Delcath Reports 2015 First Quarter Financial Results 4Delcath Reports 2015 First Quarter Financial Results 5Delcath Reports 2015 First Quarter Financial Results 6Delcath Reports 2015 First Quarter Financial Results 7Delcath Reports 2015 First Quarter Financial Results 8
... and AMSTERDAM, September 19, 2011 ... announced that a published report highlighting the development ... profile was published online in Breast Cancer ... is a part of Agendia,s Symphony™ suite of ...
... YORK, Sept. 19, 2011 Bayer HealthCare, one of ... $50,000 grant to support the Women,s International Leadership (WIL) ... external partnerships that Bayer HealthCare has established as part ... in 2008 to further develop an environment that fosters ...
Cached Medicine Technology:Breast Cancer Research and Treatment Highlights Development and Validation of BluePrint® 2Breast Cancer Research and Treatment Highlights Development and Validation of BluePrint® 3International House and Bayer HealthCare Partner to Prepare Women for Leadership Positions 2International House and Bayer HealthCare Partner to Prepare Women for Leadership Positions 3
(Date:5/6/2015)... May 06, 2015 As Hilo ... HIMSS EMR Adoption Model, the hospital looked for ... engagement and automate processes. The leadership team realized ... to electronic workflows, patient registration still required patients ... consents. With HIMSS Stage 7 attestation fast approaching, ...
(Date:5/6/2015)... Lewisberry, PA (PRWEB) May 06, 2015 A quality ... option for a functional yet practical way to raise chickens on ... coop by Chicken Coop Condo, it will have a chicken tractor ... It will last for many years, as it is able to ... help control which areas of the land are fertilized, and it ...
(Date:5/6/2015)... Experienced Vancouver air conditioning installation and ... they will now conduct their cooling services, including air ... to commercial and residential units. Strata complex air conditioning ... of technical knowledge as well as a professionally trained ... will take away any old air conditioning unit to ...
(Date:5/6/2015)... Chesapeake Regional Medical Center is the ... acquire Intuitive Surgical, Inc.’s latest model of the ... enhanced surgical technique capabilities, which can be used ... spectrum of specialties. Its advancements allow patients less ... times. , “As the only independent, community-based hospital ...
(Date:5/6/2015)... Vancouver, BC (PRWEB) May 06, 2015 ... colon hydrotherapy supplier, is excited to announce a ... will help reduce the industry’s carbon footprint while ... These kits feature Eco-Flex™, the world’s ... “This is a game-changer for hydrotherapists,” claims the ...
Breaking Medicine News(10 mins):Health News:Access Electronic Patient Signatures Help Hilo Meet HIMSS Stage 7 Paperless Targets & Save $200,000 a Year on Consent Forms 2Health News:Access Electronic Patient Signatures Help Hilo Meet HIMSS Stage 7 Paperless Targets & Save $200,000 a Year on Consent Forms 3Health News:Chicken Coop Condo Launches the Chicken Tractor 2Health News:Pro Ace Care Now Does Air Conditioning Installation for Strata Complexes 2Health News:Chesapeake Regional Medical Center Obtains First da Vinci® XI Robotic Surgical System in Virginia 2Health News:Chesapeake Regional Medical Center Obtains First da Vinci® XI Robotic Surgical System in Virginia 3Health News:World’s First Compact Colon Hydrotherapy Speculum Kit 2Health News:World’s First Compact Colon Hydrotherapy Speculum Kit 3
... , MONDAY, Nov. 22 (HealthDay News) -- The pain of ... foot, elbow and lower back pain, a new study has ... osteoarthritis (OA) patients, aged 45 to 79, about pain in ... ankle or foot. Low back pain was significantly associated ...
... the Max Delbrck Center for Molecular Medicine (MDC) Berlin-Buch, ... Award 2010" in the biology category. He will receive ... the understanding of the structure and function of GTP-binding ... two other scientists, Professor Nicolai Cramer (Lausanne, Switzerland) and ...
... , MONDAY, Nov. 22 (HealthDay News) -- If teens, ... could be compromised, a new study suggests. Teens ... providers for fear of being judged, and are reluctant ... to researchers at Cincinnati Children,s Hospital Medical Center. ...
... STANFORD, Calif. Researchers at the Stanford University School ... three-dimensional cancers in a tissue culture dish for the ... divide and invade surrounding tissue will help physicians better ... new technique also provides a way to quickly and ...
... Amounts of Urinary Protein Predict More Rapid Cognitive Decline ... Warranted A new study has found that ... not traditionally considered clinically significant, strongly predict faster cognitive ... 1,200 women aged >70 years in the Nurses, Health ...
... Reporter , FRIDAY, Nov. 19 (HealthDay News) -- Computer imaging ... look after a "nose job," and the majority value the ... "morphing" software, used by plastic surgeons since the 1990s, appears ... said. "Having an image of an individual in front ...
Cached Medicine News:Health News:For Teens, Privacy May Trump Health Care 2Health News:Stanford researchers first to turn normal cells into 3-D cancers in tissue culture dishes 2Health News:Stanford researchers first to turn normal cells into 3-D cancers in tissue culture dishes 3Health News:Protein in the urine: A warning sign for cognitive decline 2Health News:Protein in the urine: A warning sign for cognitive decline 3Health News:Computer Imaging Adds to 'Nose Job' Satisfaction: Study 2Health News:Computer Imaging Adds to 'Nose Job' Satisfaction: Study 3
... Integre Duo is the first ... and green wavelengths. This advanced,laser ... instantly,select either a red or ... maximizes,treatment options and ensures effective,patient ...
... Gathering, managing, and transmitting data ... you were hired for. Dawnings ResultNet/Plus ... running your lab, not your communications ... with transmitting result data from largescale ...
... a comprehensive hemodynamic monitoring and information ... Patient demographics, clinical hemodynamic data, ... information all flow seamlessly into one ... data entry. Both images ...
Exxcel Soft ePTFE vascular graft, designed for exceptional kink resistance and crush resistance, maintains a Soft touch for easier handling during peripheral vascular bypass procedures and vascular a...
Medicine Products: